Burns – Pipeline Review H1 2019, Covering Drug Profiles and Companies Involved in Therapeutics Development – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Burns
– Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

This latest pipeline guide Burns – Pipeline Review, H1 2019,
provides comprehensive information on the therapeutics under development
for Burns (Dermatology), complete with analysis by stage of development,
drug target, mechanism of action (MoA), route of administration (RoA)
and molecule type. The guide covers the descriptive pharmacological
action of the therapeutics, its complete research and development
history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players
involved in therapeutic development for Burns and features dormant and
discontinued projects. The guide covers therapeutics under Development
by Companies/Universities/Institutes, the molecules developed by
Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical,
Discovery and Unknown stages are 3, 3, 3, 2, 13, 4 and 2 respectively.
Similarly, the Universities portfolio in Discovery stages comprises 1
molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking
emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to
gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Burns (Dermatology).
• The pipeline guide reviews pipeline therapeutics for Burns
  (Dermatology) by companies and universities/research institutes based
  on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Burns
  (Dermatology) therapeutics and enlists all their major and minor
  projects.
• The pipeline guide evaluates Burns (Dermatology) therapeutics based on
  mechanism of action (MoA), drug target, route of administration (RoA)
  and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Burns (Dermatology).

Reasons to Buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Burns (Dermatology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Burns (Dermatology) pipeline depth and focus of Indication
  therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Companies Involved in Therapeutics Development

• AlgiPharma AS
• Alliance Pharma PLC
• Amarantus Bioscience Holdings Inc.
• Anterogen Co. Ltd.
• CFM Pharma Holding B.V.
• Destiny Pharma PLC
• Energenesis Biomedical Co. Ltd.
• Madam Therapeutics B.V.
• MallInckrodt PLC
• MediWound Ltd.
• Phagelux Inc.
• Se-cure Pharmaceuticals Ltd.
• USV Pvt Ltd.
• viDA Therapeutics Inc.

Drug Profiles

• (cerium nitrate hexahydrate + silver sulfadiazine)
• (chlorpheniramine maleate + ibuprofen)
• AGLE-102
• BH-01
• bromelains
• Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns
• Cell Therapy for Dermatology and Immunology
• ENERGIF-711
• epidermal growth factor biosimilar
• ISN-001
• Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns,
  Inflammation and Wounds
• Mul-1867
• Neu-2000
• NJ-01SS
• Oligomer G for Burn Wounds
• P-12
• Protein to Activate FGFR for Cardiovascular, CNS, Dermatology and
  Musculoskeletal Disorders
• pyrvinium pamoate
• Recombinant Protein to Agonize EPCR for Wounds and Burns
• SAAP-148
• SC-106
• SFR-9X0125
• silver sulfadiazine
• Small Molecules for Burns
• sodium hypochlorite
• Stem Cell Therapy for Burns and Dermatitis
• Synthetic Peptides for Bacterial Infections
• Tolasure
• Vanadis-02
• VTI-1002
• XF-70

Featured News & Press Releases

• Jan 23, 2019: MediWound reports positive top-line data from NexoBrid
  study
• Oct 15, 2018: Mallinckrodts Stratatech company awarded $26 million in
  additional BARDA funding for pediatric studies of stratagraft skin
  tissue in thermal burns
• Sep 24, 2018: MediWound awarded additional BARDA contract valued Up to
  $43 Million for development of NexoBrid for sulfur mustard injuries
• Sep 05, 2018: NexoBrid receives marketing authorization from Russia’s
  Ministry of Health
• Jul 18, 2018: U.S. FDA designates Mallinckrodt’s StrataGraft as
  regenerative medicine advanced therapy
• Jun 19, 2018: MediWound Expands Its NexoBrid Phase 3 Children
  Innovation Debridement Study (CIDS) to the U.S.
• Jun 11, 2018: MediWound Completes Enrollment in NexoBrid U.S. Phase 3
  DETECT Study
• Jun 04, 2018: NexoBrid Receives Marketing Authorization From South
  Koreas Ministry of Health
• Apr 09, 2018: MediWound’s NexoBrid to be Highlighted in Presentations
  at the American Burn Association 50th Annual Meeting Being Held on
  April 10-13, 2018 in Chicago
• Jan 23, 2018: Amarantus Subsidiary Cutanogen Announces Issuance of US
  Patent 14/299,480 Covering ESS, Pigmented ESS and Gene
  Therapy-Modified ESS
• Jan 04, 2018: Amarantus Subsidiary Cutanogen Announces Patent Issuance
  in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS
• Oct 31, 2017: NeoMatrix Therapeutics Enters Clinical Stage as
  Investigational New Drug Application for NMT-cP12 Goes Into Effect
• Sep 11, 2017: MediWound’s NexoBrid Wins Best Poster Presentation Award
  at the 17th European Burns Association Congress
• Sep 06, 2017: MediWounds NexoBrid Highlighted in 43 Presentations at
  the 17th European Burns Association Congress
• Jul 19, 2017: BARDA Upsizes Contract with MediWound and Exercises
  Option to Fund Further NexoBrid Indications

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/c2205l

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Dermatological
Drugs